Recombinant SARS-CoV-2 Spike antibody (RBD)
Quick Overview for Recombinant SARS-CoV-2 Spike antibody (RBD) (ABIN7271752)
Target
See all SARS-CoV-2 Spike AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
Clone
-
-
Binding Specificity
- RBD
-
Purpose
- Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (MALS verified)
-
Specificity
- This product is a specific antibody specifically reacts with This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. Cross-reactivity with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1 has not been tested.
-
Characteristics
- Recombinant Antibodies produced in HEK293. Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 is isolated from a Spike RBD infected Human and is recombinantly produced from human 293 cells (HEK293)
-
Immunogen
- The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.
-
Isotype
- IgG1
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Powder
-
Storage
- -20 °C
-
Storage Comment
- -20°C
-
-
- SARS-CoV-2 Spike
-
Background
- It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Target
-